Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | TPH1 | P17752 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560919 | 0.86 | NUDT1 (0.71) | NUDT1SMN1; SMN2KMT2AHRH4POLB | |
| SCHEMBL308850 | 0.78 | TPH1 (0.54) | NUDT1TPH1MMP9 | |
| SCHEMBL307720 | 0.78 | TPH1 (0.54) | NUDT1TPH1MMP9 | |
| SCHEMBL27894289 | 0.76 | TPH1 (0.53) | NUDT1TPH1HRH4MMP9 | |
| Ammonia Solution, Strong SCHEMBL308383 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAKMT2ACYP2D6UGT2B7 | |
| SCHEMBL17560838 | 0.75 | NUDT1 (0.88) | NUDT1TPH1HRH4GAACYP2D6 | |
| SCHEMBL20878223 | 0.75 | NUDT1 (0.88) | NUDT1TPH1HRH4GAACYP2D6 | |
| SCHEMBL4899755 | 0.74 | HRH4 (0.50) | NUDT1SMN1; SMN2KMT2AHRH4POLB | |
| SCHEMBL29394574 | 0.74 | HRH4 (0.50) | NUDT1SMN1; SMN2KMT2AHRH4POLB | |
| SCHEMBL135984 | 0.74 | HRH4 (0.50) | NUDT1SMN1; SMN2KMT2AHRH4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8093291-B2 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | NUDT1 865/4885TPH1 3/4885SMN1; SMN2 885/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | NUDT1 1052/4885TPH1 1/4885SMN1; SMN2 3954/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | NUDT1 222/4885TPH1 1/4885SMN1; SMN2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.